Takeaways: Health Canada’s acceptance of Knight Therapeutics’ New Drug Submission for Gemtesa (vibegron) moves the therapy closer to potential approval in Canada for adults with overactive bladd...
Takeaways Vertex’s suzetrigine filing is important because it could bring Canada its first new acute pain drug class in more than 20 years, which would give hospitals and payers a non-...
